Μετάβαση στο περιεχόμενο

EVALUATEPHARMA ORPHAN DRUG REPORT 2018

Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024

EvaluatePharma Orphan Drug 2018 Report EvaluatePharma Orphan Drug 2018 Report EvaluatePharma Orphan Drug 2018 Report
Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by 2024. By 2024, orphan drugs will represent over a fifth of the worldwide prescription market.

Despite a slowdown in pricing, the report shows that the mean cost per patient per year still managed to hit $147,308 in 2017, more than four times the mean cost for non-orphan drugs at $30,708.

Key highlights:

  • The mean price of the top 100 USA orphan drugs is expected to grow at an annual rate of 5.2%
  • Revlimid forecasted to be the USA’s top selling orphan drug in 2024
  • Soliris generated the highest USA revenue per patient for orphan drugs in 2017
  • Expected strong sales of Revlimid and Pomalyst will secure Celgene’s position as 2024 worldwide leader
  • Lanadelumab is the most valuable orphan drug in R&D, with a Net Present Value of $7.48bn

EvaluatePharma Orphan Drug 2018 Infographic

 

Orphan Drugs 2018

 

Πηγή 

Thanasis Chalikias Προβολή όλων

A Product Manager with expertise in pharma marketing and sales operations

Σχολιάστε

Συνδεθείτε για να δημοσιεύσετε το σχόλιο σας:

Λογότυπο WordPress.com

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό WordPress.com. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Google

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Google. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Twitter

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Twitter. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Facebook

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Facebook. Αποσύνδεση /  Αλλαγή )

Σύνδεση με %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Αρέσει σε %d bloggers: